Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology - Hemmi, Takuya; Ainai, Akira; Hashiguchi, Takao; Tobiume, Minoru; Kanno, Takayuki; Iwata-Yoshikawa, Naoko; Iida, Shun; Sato, Yuko; Miyamoto, Sho; Ueno, Akira; Sano, Kaori; Saito, Shinji; et al. (Vaccine, 2022)
Keywords: Adaptive immunity; adjuvants; Adjuvants, Immunologic; Administration, Intranasal; Allergy and Immunology; alum; Alum Compounds; Animals; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; Antigens; blood serum; CD4-positive T-lymphocytes; Clinical trials; Combined vaccines; Coronaviruses; COVID-19; COVID-19 - prevention & control; COVID-19 infection; COVID-19 Vaccines; Disease control; Experiments; FDA approval; Humans; Immune response; Immune system; Immunoglobulin A; Immunoglobulin A, Secretory; Immunoglobulin G; immunopathology; Infections; Infectious diseases; Influenza; Intranasal vaccination; Leukocytes (eosinophilic); Lung; Lung eosinophilic immunopathology; Lungs; lymph; Lymph nodes; Lymphocytes T; Mice; mRNA vaccines; Mucosa; Mutation; nasal mucosa; oligodeoxyribonucleotides; Oligonucleotides; pandemic; Pandemics; Pneumonia; protective effect; Proteins; Respiratory diseases; Respiratory syncytial virus; Respiratory tract; respiratory tract diseases; Risk; SARS-CoV-2; secretory IgA antibody; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus; Spike protein; Vaccination; Vaccines; Viral diseases; Viral infections; Viruses; γ-Interferon; Japan; COVID-19; SARS-CoV-2; secretory IgA antibody; Intranasal vaccination; Lung eosinophilic immunopathology